BCLI: BrainStorm Cell Therapeutics Inc. 2019-02-22 07:30:00 BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
Completing. Watch for up channel to be established. Put on watch list.
Stock is considered oversold and has been popping up on scanners as such. It is trading at at $2.96 at should be in the $4 range. This offers a 35% possible return. There is a possible support level at $2.85 due to all the sideways trending candles. Waiting for the first green day to buy this.
Its in a wedge after a pretty sharp uptrend and is seeing support at 3.80, looks like its about to break out of the wedge and it reports earnings after close today so that could be a catalyst. MACD is close to bullishly crossing over and price oscillator is close to bullishly crossing over its moving average. Its getting close to its 2/3 line which could be a...
NASDAQ:BCLI BCLI is a flag from a previous uptrend. Its earnings report is the 23rd and that could be a potential bullish or bearish catalyst. Potential buy signals are if Price Oscillator sees support at its moving average, MACD positively crosses over, Parabolic SAR gives a buy signal. RSI will be a good sell indicator when it sees previous overbought levels,...